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Viral Enhancer Mimicry of Host Innate-Immune
Promoters
Kai A. Kropp1¤*, Ana Angulo2, Peter Ghazal1,3*
1Division of Pathway Medicine and Edinburgh Infectious Diseases, University of Edinburgh, Edinburgh, United Kingdom, 2 Facultad de Medicina, Institut d’Investigacions
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The inflammatory milieu is the natural
habitat for a pathogenic infection, char-
acterised by activity of pro-inflammatory
signalling pathways and inflammatory
cytokines. Viral entry rapidly activates a
range of innate-immune signalling events
such as the activation of Pattern Recogni-
tion Receptors (PRRs) [1–5]. A virus must
therefore counteract intrinsic cellular and
innate-immune responses to successfully
complete the replication cycle. Frequently
this is accomplished by encoding viral
effector molecules that block these cellular
responses by working as either structural
or functional mimics of host target pro-
teins [6–11]. Nuclear DNA viruses are
dependent on the host transcriptional
machinery to express the first viral genes;
for example the immediate-early (IE)
control elements of DNA viruses are by
definition absolutely dependent on host
transcription factors (TF) [12]. Therefore,
these viruses are particularly hostage to
their host transcriptional environment
[13,14]. Here we propose that mimicry
of regulatory DNA sequences by viral
regulatory regions may also provide an
additional strategy to counteract at IE
times of infection the innate-immune
response. In this context, viral IE control
elements might functionally mimic innate-
immune enhancers, taking advantage of
the activated immune signalling TFs for
promoting viral IE gene expression.
In other words: ‘‘If you can’t beat
‘em. Join ‘em.’’
In exploring this possibility, we present
a synopsis of the promoter-regulatory
elements from seven extensively studied
mammalian viruses with a DNA stage, and
seven promoters representing prototypical
cellular innate-immune genes. These are
the SV-40 early enhancer, the E1A
enhancer of HAdV5, the long terminal
repeat (LTR) of HIV-1, the E6/7 long
control region (LCR) of both HPV-16 and
HPV-18, the major IE (MIE) enhancer of
HCMV, and the enhancer-1 (Eh-1) regu-
latory region of HBV for viral sequences,
and the enhancer regions of human
IFNB1, IFNG, TNF, IRF1, IL8, IL12B,
and IL1B for host sequences. First, we
consider similarities between the primary
sequence structures of the enhancers.
Second, we present arguments for conver-
gent evolution and structural flexibility
inherent to enhancer sequences. Third, we
discuss functional features and regulatory
hallmarks that may be used to define viral
enhancer mimicry of cellular immune
enhancers.
Do Viral and Cellular Enhancers
Display Any Primary Sequence
Similarity?
To investigate if there is any similarity
of primary sequences and therefore struc-
tural mimicry between the selected viral
and cellular enhancers, we used the
BLAST tool to compare the sequences
against each other (Table 1) and applied
an exhaustive pairwise multi-way align-
ment (CloneManager suite 7.0) to search
for similarities in this group of sequences
(Figure 1A). While multi-way alignment of
the various selected viral and cellular
promoter-regulatory regions (Figure 1A,
top panel) reveals a lack of extended
primary sequence homology, the pairwise
BLAST comparison showed that small
islands of sequence identity or high
similarity are present (Table 1). We
randomly compared some of these short
sequence motifs with the JASPAR CORE
(Vertebrae) database [15] and found that
all checked motifs have similarities with
consensus binding motifs for TFs (e.g.,
AP1, SP1, YY1, or RelA with relative
scores of .0.8). This finding raises the
question of whether there might be
functional similarity. We therefore consid-
er in the next section how convergent
evolution of viral enhancers may have
resulted in functional mimicry of the
transcription control elements of innate-
immune genes, providing a co-opting
strategy for immune evasion.
Could Viral Regulatory Regions
Evolve as Functional Mimics of
Innate-Immune Enhancers
without Extensive Sequence
Similarity?
There are two principal genetic mech-
anisms that could lead to viral mimicry of
host enhancers, horizontal transfer of
cellular sequences to viral genomes or
genetic drift of viral sequences. The first
possibility, acquisition of cellular sequenc-
es through horizontal sequence transfer,
could arise through illegitimate recombi-
nation with host DNA, for example by
retro-transposition of non-coding RNA
transcripts, resulting in the virus hijacking
host transcription control sequences. If this
were the general case, we would, however,
expect significant structural similarity,
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which we did not find in our analysis.
Alternatively, but not mutually exclusive
from horizontal transfer, viral enhancer
mimics could arise through neutral evolu-
tion and genetic drift by sequence dupli-
cation or accumulation of point mutations.
Duplicated sequence features are hall-
marks for many viral and cellular enhanc-
ers [16–24]. For instance, deletion or loss
of enhancer sequences in SV40 and JC
polyomavirus promotes restoration of en-
hancer function through duplication of
flanking sequences [25–28]. A third possi-
bility is the accumulation of point mutations
in enhancer sequences and subsequent
fixation [29]. It has recently been described
for a wide range of species that evolution of
host-cell transcriptional control can occur
in relatively short time spans and is mainly
driven by the rapid and flexible emergence
or loss of binding motifs rather than by
evolution of the TF proteins themselves
[30–36]. The described mechanisms of
rapid enhancer evolution argue that viral
enhancers could acquire functionality that
mimics innate-immune enhancers without
any extensive sequence homology, and this
is consistent with the comparison of cellular
and viral enhancers shown in Figure 1A.
This possibility is underscored by the fact
that promoter sequences seem to be poorly
conserved even among members within a
virus-family yet share many of the same
regulatory elements [37]. For example the
MIE enhancers of cytomegaloviruses show
low levels of primary sequence similarity
between the different species strains
(Figure 1A, lower panel). Despite these
differences, functionality of the enhancers is
conserved between hosts for different CMV
species strains, e.g., the human CMV
enhancer can functionally complement
deletion of the murine CMV enhancer
[38] and human CMV enhancer sequences
recapitulate in vivo biological sites of
infection in species from mice to zebra fish
[39–41].
What Features Would Classify a
Viral Enhancer as an Innate-
Immune Enhancer Mimic?
Since our work and that of others
discussed so far indicates that viral enhanc-
ers are functional rather than structural
mimics of host innate-immune enhancers,
we suggest four principal hallmarks of
functional enhancer mimicry. These are:
1) shared TF interactions independent of
sequence structure, 2) similar kinetics of
gene induction between cellular innate-
immune and viral IE genes, 3) positive
responsiveness to immune-stimulatory li-
gands, and 4) susceptibility to inhibition of
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Table 2. List of identified interactions for the selected viral and host enhancers.
TF Name Entrez Gene ID Protein Family TF Name Entrez Gene ID Protein Family
NFKB1 (p50) 4790 NFkB MYOF 26509 Ferlin
RelA (p65) 5970 NFkB HSF1 3297 HSF
RelC 5966 NFkB ELK1 2002 ETS
NFkB2 (p52) 4791 NFkB SRF 6722 SRF
C/EBP N/A (generic) C/EBP RAR 5914 Nuclear hormone receptor
CREB1 1385 bZIP RXR 6256 Nuclear hormone receptor
ATF1 466 AP ETS2 2114 ETS
ATF2 1386 AP GAP12 Unspecified Unspecified
AP1/Jun 3725 AP NRF (NKRF) 55922 N/A
FOS 2353 AP NF1 4763 Nuclear hormone receptor
SP1 6667 C2H2-zinc finger GRE/NR3C1 N/A (generic) Nuclear hormone receptor
SPI1 6688 ETS AP2 7020 AP
HMGI(Y) 3159 HMG AP3 Unspecified Unspecified
OCT 1 5451 OCT/POU USF1 7391 Helix-loop-helix leucine zipper
OCT 2 5452 OCT/POU TFE3 7030 MiT/TFE
IRF1 3659 IRF LEF1 51176 TCF/LEF
IRF2 3660 IRF ETS1 2113 ETS
IRF3 3661 IRF OTK18 7728 Krueppel C2H2-zinc finger
IRF7 3665 IRF E2F1 1869 EF
STAT1 6772 STAT BCL3 602 N/A
STAT2 6773 STAT SP3 6670 C2H2-zinc finger
STAT3 6774 STAT ERF 2077 ETS
STAT4 6775 STAT GFI1 2672 C2H2-zinc finger
NFATp/NFATc 4773/511224 NFAT CUX1 1523 N/A
NFIL6 1051 bZIP E1A 6870514 Adenoviridae E1A protein
YY1 7528 YY E4F1 1877 EF
TBX21 30009 T-BOX TAF1 6872 TAF1
EOMES 8320 T-BOX HBS1L 10767 N/A
PPAR N/A (generic) Nuclear hormone
receptor
HNF1 6927 Hepatic nuclear factor
PPARG/PROX1 5468/5629 Nuclear hormone
receptor
HNF3 2305 Hepatic nuclear factor
SMAD3 4088 SMAD HNF4 3172 Hepatic nuclear factor
RUNX3 864 N/A RFX1 5989 RFX
PRDM1/PRDI BF1 639 C2H2-zinc finger PX 944566 Orthohepadnavirus protein X
HIVEP2/PRDII BF1 3097 C2H2-zinc finger C-abl 25 Tyr protein kinase family
HIVEP1 3096 C2H2-zinc finger NR2F1/COUP-TF 7025 Nuclear hormone receptor
NREBP 6651 N/A PEF1 553115 Penta-EF-hand protein
doi:10.1371/journal.ppat.1003804.t002
Figure 1. Comparison of host innate-immune and viral regulatory regions. A) Multi-way alignment of analysed enhancer sequences shows
no sequence similarity. Narrow grey boxes mark AT-rich stretches and dark grey boxes mark GC-rich stretches. Overall, sequence similarity was too
low to produce a phylogenetic tree. To analyse sequence similarity within one family of viruses, we compared the major immediate-early enhancer
region of rat-CMV (RCMV) with those of human (HCMV), murine (MCMV), chimpanzee (CCMV) and rhesus (RHCMV) cytomegalovirus. Small stretches
of sequences similarity to the RCMV sequence are indicated by wide light grey boxes (similarity .80%). B) Venn diagram of 72 TFs identified in our
literature search to interact with the analysed regulatory sequences. Detailed SBGN diagrams of all elements and interactions can be found at [46–52]
except for TNF [57]. C) Simplified summary of transcription factor families shared between analysed innate-immune regulatory regions and viral
control elements. For simplification interactions with members belonging to a family of TFs are represented by only one symbol (e.g., p50, p65, and
RelA interactions are all represented by the ‘‘NFkB’’ symbol). The summary was produced in the ‘‘MSc by research in genomics and pathway biology’’
project by literature review. Digits in brackets indicate the number of shared interactions (left of dash) and total number of interactions for the
specific enhancer (right of dash). TFs that are more highly connected with viral and host elements were placed toward the centre.
doi:10.1371/journal.ppat.1003804.g001
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inflammatory signalling. In the following
section we briefly discuss these hallmarks.
Shared Transcription Factor
Interactions
The human genome encodes an estimat-
ed 1,700 to 1,900 TFs, with 1,391 repre-
senting high-confidence candidates [42].
These proteins represent an ample resource
for viruses to harness. To probe, in more
detail, the TF usage of the 14 viral and
innate-immune enhancers selected (Table 1),
we constructed unambiguous diagrams [43–
45] of known TF interactions—available as
an online resource on Figshare [46–52].
Using this approach we identified 72
interactions (Table 2) between the selected
host and viral regulatory regions and host
TFs. Of the 72 interactions identified, 43
were described for cellular enhancers and 50
for viral enhancers and 21 interactions (49%
and 42% respectively) are shared among
innate-immune enhancers and viral enhanc-
ers (Figure 1B). Annotation of this dataset
using the BioMART tool (v0.7, ENSEMBL
release v72) identified 31 TFs associated
with ‘‘regulation of immune processes’’
[GO:0002376] in our 72 identified interac-
tions. Notably, the extent to which the
distinct viral enhancers share factorswith the
innate-immune genes varies (Figure 1C).
This may be explained by the different
physiological roles of the innate-immune
genes and lifestyles of the selected viruses.
Among the viruses, HCMV and HIV-1 en-
hancers show the largest TF overlap in total
numbers of interactions with the innate-
immune genes. In summary, we identified a
substantial overlap in TF interactions be-
tween host and viral regulatory regions.
Comparable Expression Kinetics
It is noteworthy that host immediate-
early response genes and viral immediate-
early genes are, by definition, identified by
the same criterion, namely that their
expression is independent of newly syn-
thesised proteins [12,53,54]. Upon infec-
tion of permissive cells, viral promoters are
activated within the first hour of infection.
This follows a typical expression profile
with a peak between 2–6 h followed by
reduced expression levels. This expression
pattern has parallels with the temporal
expression of host innate-immune genes,
e.g., IFNB1, IL6, or TNF that are rapidly
induced after PRR activation [55–58].
Most notably, it has recently been dem-
onstrated in a genome-wide transcriptome
study with murine CMV that the mRNA
synthesis rate of viral IE transcripts is
rapidly induced and subsequently strongly
downregulated, following the expression
kinetic profile for many innate immune
genes in this dataset [59].
Response to Immune-Stimulatory
Ligands
A corollary of viral enhancer mimicry of
innate-immune regulatory functions is that
the viral promoters/enhancers should be
activated by the same signalling events as
innate-immune genes. This implies that
events during the infection process that
trigger ‘‘antiviral’’ signalling cascades actually
facilitate the initial viral transcription. In this
context, it has been shown that activation of
TLRs by LPS and CpG [60,61] increases
activity in isolated HCMV-enhancer and
HIV-LTR–driven reporter constructs [62–
64]. This also seems to apply in the context of
viral infection since cytokine signalling stim-
ulates HBV gene expression [65] and HIV
needs TLR-8 signalling in specific cell types
for replication [66]. It is also notable that all
of the viral control regions examined here
have been shown to interact with AP-1
(Figure 1C). While AP-1 is not exclusively
associated with innate-immune signalling,
it can be activated by TLR signalling
via MAPK-activation or by cAMP-related
signalling during infection [67,68] and sub-
sequently also binds to innate-immune en-
hancers. Taken together, these examples
indicate that so called ‘‘antiviral’’ processes
have the potential to facilitate viral IE gene
expression and replication. In the future, their
importance and potentially proviral role
should be examined in viral infection models.
Responsiveness to Negative
Feedback Control
Immune signalling pathways are tightly
regulated by negative feedback with the
inhibitors of signalling activity acting in a
matter of minutes to hours [69,70]. Thus,
innate-immune negative feedback loops
should also inhibit viral gene expression
and may play a role in viral latency. This
hallmark of viral enhancer mimicry might
prove the most challenging for scientific
investigation. Interference with negative
feedback regulators before infection may
lead to an exacerbated immune response,
either inducing an elevated antiviral state in
the cell before the experimental infection or
driving it into apoptosis. Still, proving that
this hallmark is applicable to viral infections
might provide new drug targets to inhibit
viral infections. While, to our knowledge,
no direct effects of negative regulators of
inflammatory signalling on viral gene
expression have been reported so far, it
has been shown that anti-inflammatory
drugs and chemical inhibitors of pro-
inflammatory signalling, expected to in-
crease viral replication, actually can inhibit
viral gene expression and replication of
HCMV, HBV, and HIV-1 [67,68,71–74].
Concluding Remarks
TFs activating innate-immune genes are
regulated by PRR signalling that cannot be
efficiently inhibited by viruses as their
activation occurs during the viral entry pro-
cess. Mimicking an innate-immune enhanc-
er therefore has the advantage that TFs,
already activated by the viral entry process,
can be directly utilised in a time restricted
manner to ensure viral gene expression at IE
times. We hope this opinion opens debate
and provides new insights for either reex-
amination or future-based investigations
toward understanding viral gene activation
and latency. Indeed we believe that the
principle of viruses co-opting host-innate
regulatory signals has broad implications
toward understanding the biological role of
viral enhancers, in acute and latent viral
infections, and prospective host-directed
antiviral therapeutic and vaccine strategies.
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